Clinical Trials
2 trialsNCT03719898 2021-01-05
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT04260009 2020-03-05
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
Takeda
Phase 1/2 Withdrawn